Pharmacotherapeutic Options for Managing Neuropathic Pain: A Systematic Review and Meta-Analysis

Table 6

Randomized, double-blind, controlled trials testing the effect of sodium channel blockers.

Reference	Active drug	Control	Sample size	NP condition	Outcome measure	Pain outcome	Adverse events
de Greef et al. [33]	Lacosamide 400 mg	Placebo	47	Nav1.7-related SFN	0–10 NRS	Positive	Dizziness (41.7), nausea (25%), headache (25%), fatigue (20.8%), tremor (20.8%), somnolence (16.7%), epigastric discomfort (16.7%), memory impairment (12.5%), and pruritus (12.5%)
Mc Donnell et al. [34]	PF-05089771 300 mg	Placebo	135	DPN	0–10 NRS	Negative	Constipation (5%), back pain (1%) headache (1%), and pollakiuria (1%)
Zakrzewska et al. [35]	BIIB074 450 mg	Placebo	67	TN	Number of treatment failures	Negative	Headache (19%), dizziness (9%), dyspepsia (6%), diarrhoea (6%), abdominal pain (6%), and fatigue (6%)
Price et al. [36]	TV-45070 ointment	Placebo	70	PHN	Mean daily pain score	Negative	Application site pain (15.9%), application site pruritus (12.7%), and infections (17.5%)

NP: neuropathic pain; SFN: small-fibre neuropathy; DPN: diabetic painful neuropathy; TN: trigeminal neuralgia; PHN: postherpetic neuralgia; NRS: numerical rating scale.